Hexima Ltd · ASX:HXL
Hexima — Shareholder Meeting (November 2016)
20 slides from Hexima's shareholder meeting presentation, Nov 22, 2016
Slide 1: Annual General Meeting 2016
Annual General Meeting 2016 KPMG Theatrette Ground Floor 147 Collins St Melbourne Tuesday 22 November 2016 11.00am
Slide 2: Forward looking statements
Forward looking statements Certain statements in this presentation relate to the future, including forward looking statements relating to Hexima’s future expectations, beliefs, goals, plans, prospects, financial position and strategy. These forward looking statements involve known and unknown risks,
Slide 3: AGM 2016 – Chairman
AGM 2016 Professor Jonathan West – Chairman
Slide 4: AGM 2016 – Chief Executive Officer
AGM 2016 Dr Nicole van der Weerden – Chief Executive Officer
Slide 5: Hexima Limited
Hexima Limited Research labs located in the La Trobe Institute for Molecular Science (LIMS) • 28 research scientists • 5 administration staff • 2 PhD students Greenhouse facilities located at the La Trobe R&D Park • PC2 accredited facility • Nine individual compartments —several compartments lease
Slide 6: Hexima's technology platforms
Hexima’s technology platforms Antifungal • Human applications – fungal nail infections (onychomycosis) • Plant applications – transgenic crops, fungicides for seed coatings and crop sprays Income generating programs • Insecticidal gene discovery program – crop protection • Leasing of greenhouse fa
Slide 7: Key achievements for 2016
Key achievements for 2016 HXP124, our lead for the treatment of fungal nail infections, as effective as current topical ‘gold standard’ in an in vitro infected toenail model. Formulation of HXP124 for clinical trials completed. Extensive pre-clinical toxicology program for HXP124 almost complete.
Slide 8: Insecticidal gene discovery program
Insecticidal gene discovery program Collaboration funded by DuPont-Pioneer since 2014 for discovery of insect-active genes for crop protection. Royalties to Hexima for any commercial outcomes. Timeline for a substantial cash return from this project is long (>5 years) but project is generating va
Slide 9: Multi Gene Expression Vehicle (MGEV)
Multi Gene Expression Vehicle (MGEV) A technology that improves trait development in transgenic plants • Allows construction of genes that code for more than one protein. Without MGEV • Reduces the need for additional regulatory Promoter Protein 1 Terminator Promoter Protein 2 Terminator elements •
Slide 10: Plant antifungal
Plant antifungal Hexima has discovered several antifungal peptide combinations that provide protection against fungal disease in cotton or corn. Hexima is looking for a suitable partner Control lines Transgenic lines to continue development of this Hexima AFPs make corn more resistant to fungal di
Slide 11: Fungi that infect plants and humans are very similar
Fungi that infect plants and humans are very similar F. oxysporum T. rubrum (plant pathogen) (nail pathogen) Hexima’s proprietary antifungal molecules are effective against both plant and human pathogens. 11
Slide 12: Global onychomycosis market
Global onychomycosis market US$3.06 billion in 2015 and projected to reach US$4.7 billion by 2021. Major deficiencies in current therapies. • Poor efficacy rates • Long treatment times • Oral therapies can be toxic • Expensive —Estimated that between 50 and 90% of individuals with fungal nail infe
Slide 13: Global onychomycosis products
Global onychomycosis products Approved Topical Therapies for Onychomycosis Loceryl® Penlac®/Rejuvenail® KERYDIN® Jublia® (5% Amorolfine) (8% Ciclopirox) (5% Tavaborole) (10% Efinaconazole) 48 week treatment 48 week treatment 48 week treatment 48 week treatment ~US$160 ~US$830 ~US$8,400 ~US$8,400 1-2
Slide 14: HXP124
HXP124 Hexima is developing a novel therapeutic (HXP124) for the treatment of fungal nail infections (onychomycosis). HXP124 has the potential to be superior to current therapies. • Potent, broad-spectrum antifungal molecule —Member of the Plant Defensin class of molecules • Penetrates nails faste
Slide 15: HXP124 is as effective as Jublia in an infected nail model
HXP124 is as effective as Jublia® in an infected nail model MedPharm (UK) tested HXP124 in an 2. HXP124 applied topically “infected nail model” and confirmed that HXP124 passes through nails and kills fungal cells on the other side. nail adapter • Industry standard assay. human nail • Nail and fung
Slide 16: HXP124 is as effective as Jublia in an infected nail model
HXP124 is as effective as Jublia® in an infected nail model 40% ATP levels* (% relative to infected control) 30% 20% 10% 0% HXP124 Jublia® Penlac® HXP124 Jublia® Penlac® HXP124 Jublia® 7 days 14 days 21 days *ATP levels are used as a measure of cell survival 16
Slide 17: HXP124 development plan
HXP124 development plan 2015 2016 2017 2018 Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Manufacture Scale up of manufacture under GMP conditions Production of material for clinical trials Preclinical Formulat
Slide 18: HXP124 commercialisation plan
HXP124 commercialisation plan Positive data from phase I/IIa clinical trials will be a significant value creation step. If positive clinical efficacy data is obtained, Hexima will licence HXP124 to a pharmaceutical companie(s) to generate upfront and future milestone payments and licensing revenue
Slide 19: Defensin platform applicable to other fungal diseases
Hexima’s defensin platform is applicable to other fungal diseases Vulvovaginal candidiasis (thrush) • HXP124 and other Hexima lead antifungals rapidly kill Candida spp • HXP124 is stable in a topical formulation which is a significant advantage for this application Fungal infections of traumatic i
Slide 20: Summary
Summary Hexima has developed a defensin platform applicable to a range of applications. Hexima is developing HXP124 as a superior therapeutic for onychomycosis. • Better nail penetration. • Rapidly kills fungal cells. • Anticipating shorter treatment regimen. —4 weeks vs 48 weeks. Hexima expects